Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer.
Puglisi F, Gerratana L, Lambertini M, Ceppi M, Boni L, Montemurro F, Russo S, Bighin C, De Laurentiis M, Giuliano M, Bisagni G, Durando A, Turletti A, Garrone O, Ardizzoni A, Gamucci T, Colantuoni G, Gravina A, De Placido S, Cognetti F, Del Mastro L.
Puglisi F, et al. Among authors: de placido s, de laurentiis m.
NPJ Breast Cancer. 2021 Jun 28;7(1):82. doi: 10.1038/s41523-021-00286-w.
NPJ Breast Cancer. 2021.
PMID: 34183674
Free PMC article.